Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.
OBJECTIVE: To determine whether the immunogenicity of a single dose infant priming schedule of serogroup C meningococcal (MenC) conjugate vaccine is non-inferior to a two dose priming schedule when followed by a booster dose at age 12 months. DESIGN: Phase IV open label randomised controlled trial c...
| Hoofdauteurs: | , , , , , , , , , , , , , , , |
|---|---|
| Formaat: | Journal article |
| Taal: | English |
| Gepubliceerd in: |
BMJ Publishing Group
2015
|
| _version_ | 1826266102373548032 |
|---|---|
| author | Pace, D Khatami, A McKenna, J Campbell, D Attard-Montalto, S Birks, J Voysey, M White, C Finn, A Macloed, E Faust, S Kent, A Heath, P Borrow, R Snape, M Pollard, A |
| author_facet | Pace, D Khatami, A McKenna, J Campbell, D Attard-Montalto, S Birks, J Voysey, M White, C Finn, A Macloed, E Faust, S Kent, A Heath, P Borrow, R Snape, M Pollard, A |
| author_sort | Pace, D |
| collection | OXFORD |
| description | OBJECTIVE: To determine whether the immunogenicity of a single dose infant priming schedule of serogroup C meningococcal (MenC) conjugate vaccine is non-inferior to a two dose priming schedule when followed by a booster dose at age 12 months. DESIGN: Phase IV open label randomised controlled trial carried out from July 2010 until August 2013 SETTING: Four centres in the United Kingdom and one centre in Malta. PARTICIPANTS: Healthy infants aged 6-12 weeks followed up until age 24 months. INTERVENTIONS: In the priming phase of the trial 509 infants were randomised in a 10:10:7:4 ratio into four groups to receive either a single MenC-cross reacting material 197 (CRM) dose at 3 months; two doses of MenC-CRM at 3 and 4 months; a single MenC-polysaccharide-tetanus toxoid (TT) dose at 3 months; or no MenC doses, respectively. Haemophilus influenzae type b (Hib)-MenC-TT vaccine was administered to all infants at 12 months of age. All infants also received the nationally routinely recommended vaccines. Blood samples were taken at age 5, 12, 13, and 24 months. MAIN OUTCOME MEASURE: MenC serum bactericidal antibody assay with rabbit complement (rSBA) one month after the Hib-MenC-TT vaccine. Non-inferiority was met if the lower 95% confidence limit of the difference in the mean log10 MenC rSBA between the single dose MenC-CRM and the two dose MenC-CRM groups was >-0.35. RESULTS: The primary objective was met: after a Hib-MenC-TT booster dose at 12 months of age the MenC rSBA geometric mean titres induced in infants primed with a single MenC-CRM dose were not inferior to those induced in participants primed with two MenC-CRM doses in infancy (660 (95% confidence interval 498 to 876) v 295 (220 to 398)) with a corresponding difference in the mean log10 MenC rSBA of 0.35 (0.17 to 0.53) that showed superiority of the single over the two dose schedule). Exploration of differences between the priming schedules showed that one month after Hib-MenC-TT vaccination, MenC rSBA ≥ 1:8 was observed in >96% of participants previously primed with any of the MenC vaccine schedules in infancy and in 83% of those who were not vaccinated against MenC in infancy. The MenC rSBA geometric mean titres induced by the Hib-MenC-TT boost were significantly higher in children who were primed with one rather than two MenC-CRM doses in infancy. Only priming with MenC-TT, however, induced robust MenC bactericidal antibody after the Hib-MenC-TT booster that persisted until 24 months of age. CONCLUSIONS: MenC vaccination programmes with two MenC infant priming doses could be reduced to a single priming dose without reducing post-boost antibody titres. When followed by a Hib-MenC-TT booster dose, infant priming with a single MenC-TT vaccine dose induces a more robust antibody response than one or two infant doses of MenC-CRM. Bactericidal antibody induced by a single Hib-MenC-TT conjugate vaccine dose at 12 months of age (that is, a toddler only schedule), without infant priming, is not well sustained at 24 months. Because of rapid waning of MenC antibody, programmes using toddler only schedules will still need to rely on herd protection to protect infants and young children.Trial registration Eudract No: 2009-016579-31; NCT01129518; study ID: 2008_06 (http://clinicaltrials.gov). |
| first_indexed | 2024-03-06T20:33:50Z |
| format | Journal article |
| id | oxford-uuid:31f566e6-0d0c-4b34-b6cf-f519fb994ecf |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:33:50Z |
| publishDate | 2015 |
| publisher | BMJ Publishing Group |
| record_format | dspace |
| spelling | oxford-uuid:31f566e6-0d0c-4b34-b6cf-f519fb994ecf2022-03-26T13:11:07ZImmunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:31f566e6-0d0c-4b34-b6cf-f519fb994ecfEnglishSymplectic Elements at OxfordBMJ Publishing Group2015Pace, DKhatami, AMcKenna, JCampbell, DAttard-Montalto, SBirks, JVoysey, MWhite, CFinn, AMacloed, EFaust, SKent, AHeath, PBorrow, RSnape, MPollard, AOBJECTIVE: To determine whether the immunogenicity of a single dose infant priming schedule of serogroup C meningococcal (MenC) conjugate vaccine is non-inferior to a two dose priming schedule when followed by a booster dose at age 12 months. DESIGN: Phase IV open label randomised controlled trial carried out from July 2010 until August 2013 SETTING: Four centres in the United Kingdom and one centre in Malta. PARTICIPANTS: Healthy infants aged 6-12 weeks followed up until age 24 months. INTERVENTIONS: In the priming phase of the trial 509 infants were randomised in a 10:10:7:4 ratio into four groups to receive either a single MenC-cross reacting material 197 (CRM) dose at 3 months; two doses of MenC-CRM at 3 and 4 months; a single MenC-polysaccharide-tetanus toxoid (TT) dose at 3 months; or no MenC doses, respectively. Haemophilus influenzae type b (Hib)-MenC-TT vaccine was administered to all infants at 12 months of age. All infants also received the nationally routinely recommended vaccines. Blood samples were taken at age 5, 12, 13, and 24 months. MAIN OUTCOME MEASURE: MenC serum bactericidal antibody assay with rabbit complement (rSBA) one month after the Hib-MenC-TT vaccine. Non-inferiority was met if the lower 95% confidence limit of the difference in the mean log10 MenC rSBA between the single dose MenC-CRM and the two dose MenC-CRM groups was >-0.35. RESULTS: The primary objective was met: after a Hib-MenC-TT booster dose at 12 months of age the MenC rSBA geometric mean titres induced in infants primed with a single MenC-CRM dose were not inferior to those induced in participants primed with two MenC-CRM doses in infancy (660 (95% confidence interval 498 to 876) v 295 (220 to 398)) with a corresponding difference in the mean log10 MenC rSBA of 0.35 (0.17 to 0.53) that showed superiority of the single over the two dose schedule). Exploration of differences between the priming schedules showed that one month after Hib-MenC-TT vaccination, MenC rSBA ≥ 1:8 was observed in >96% of participants previously primed with any of the MenC vaccine schedules in infancy and in 83% of those who were not vaccinated against MenC in infancy. The MenC rSBA geometric mean titres induced by the Hib-MenC-TT boost were significantly higher in children who were primed with one rather than two MenC-CRM doses in infancy. Only priming with MenC-TT, however, induced robust MenC bactericidal antibody after the Hib-MenC-TT booster that persisted until 24 months of age. CONCLUSIONS: MenC vaccination programmes with two MenC infant priming doses could be reduced to a single priming dose without reducing post-boost antibody titres. When followed by a Hib-MenC-TT booster dose, infant priming with a single MenC-TT vaccine dose induces a more robust antibody response than one or two infant doses of MenC-CRM. Bactericidal antibody induced by a single Hib-MenC-TT conjugate vaccine dose at 12 months of age (that is, a toddler only schedule), without infant priming, is not well sustained at 24 months. Because of rapid waning of MenC antibody, programmes using toddler only schedules will still need to rely on herd protection to protect infants and young children.Trial registration Eudract No: 2009-016579-31; NCT01129518; study ID: 2008_06 (http://clinicaltrials.gov). |
| spellingShingle | Pace, D Khatami, A McKenna, J Campbell, D Attard-Montalto, S Birks, J Voysey, M White, C Finn, A Macloed, E Faust, S Kent, A Heath, P Borrow, R Snape, M Pollard, A Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial. |
| title | Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial. |
| title_full | Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial. |
| title_fullStr | Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial. |
| title_full_unstemmed | Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial. |
| title_short | Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial. |
| title_sort | immunogenicity of reduced dose priming schedules of serogroup c meningococcal conjugate vaccine followed by booster at 12 months in infants open label randomised controlled trial |
| work_keys_str_mv | AT paced immunogenicityofreduceddoseprimingschedulesofserogroupcmeningococcalconjugatevaccinefollowedbyboosterat12monthsininfantsopenlabelrandomisedcontrolledtrial AT khatamia immunogenicityofreduceddoseprimingschedulesofserogroupcmeningococcalconjugatevaccinefollowedbyboosterat12monthsininfantsopenlabelrandomisedcontrolledtrial AT mckennaj immunogenicityofreduceddoseprimingschedulesofserogroupcmeningococcalconjugatevaccinefollowedbyboosterat12monthsininfantsopenlabelrandomisedcontrolledtrial AT campbelld immunogenicityofreduceddoseprimingschedulesofserogroupcmeningococcalconjugatevaccinefollowedbyboosterat12monthsininfantsopenlabelrandomisedcontrolledtrial AT attardmontaltos immunogenicityofreduceddoseprimingschedulesofserogroupcmeningococcalconjugatevaccinefollowedbyboosterat12monthsininfantsopenlabelrandomisedcontrolledtrial AT birksj immunogenicityofreduceddoseprimingschedulesofserogroupcmeningococcalconjugatevaccinefollowedbyboosterat12monthsininfantsopenlabelrandomisedcontrolledtrial AT voyseym immunogenicityofreduceddoseprimingschedulesofserogroupcmeningococcalconjugatevaccinefollowedbyboosterat12monthsininfantsopenlabelrandomisedcontrolledtrial AT whitec immunogenicityofreduceddoseprimingschedulesofserogroupcmeningococcalconjugatevaccinefollowedbyboosterat12monthsininfantsopenlabelrandomisedcontrolledtrial AT finna immunogenicityofreduceddoseprimingschedulesofserogroupcmeningococcalconjugatevaccinefollowedbyboosterat12monthsininfantsopenlabelrandomisedcontrolledtrial AT macloede immunogenicityofreduceddoseprimingschedulesofserogroupcmeningococcalconjugatevaccinefollowedbyboosterat12monthsininfantsopenlabelrandomisedcontrolledtrial AT fausts immunogenicityofreduceddoseprimingschedulesofserogroupcmeningococcalconjugatevaccinefollowedbyboosterat12monthsininfantsopenlabelrandomisedcontrolledtrial AT kenta immunogenicityofreduceddoseprimingschedulesofserogroupcmeningococcalconjugatevaccinefollowedbyboosterat12monthsininfantsopenlabelrandomisedcontrolledtrial AT heathp immunogenicityofreduceddoseprimingschedulesofserogroupcmeningococcalconjugatevaccinefollowedbyboosterat12monthsininfantsopenlabelrandomisedcontrolledtrial AT borrowr immunogenicityofreduceddoseprimingschedulesofserogroupcmeningococcalconjugatevaccinefollowedbyboosterat12monthsininfantsopenlabelrandomisedcontrolledtrial AT snapem immunogenicityofreduceddoseprimingschedulesofserogroupcmeningococcalconjugatevaccinefollowedbyboosterat12monthsininfantsopenlabelrandomisedcontrolledtrial AT pollarda immunogenicityofreduceddoseprimingschedulesofserogroupcmeningococcalconjugatevaccinefollowedbyboosterat12monthsininfantsopenlabelrandomisedcontrolledtrial |